Cargando…
Rationale for MYC imaging and targeting in pancreatic cancer
The incidence and lethality of pancreatic ductal adenocarcinoma (PDAC) will continue to increase in the next decade. For most patients, chemotherapeutic combination therapies remain the standard of care. The development and successful implementation of precision oncology in other gastrointestinal tu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511206/ https://www.ncbi.nlm.nih.gov/pubmed/34637026 http://dx.doi.org/10.1186/s13550-021-00843-1 |
_version_ | 1784582723014230016 |
---|---|
author | Schneider, Günter Wirth, Matthias Keller, Ulrich Saur, Dieter |
author_facet | Schneider, Günter Wirth, Matthias Keller, Ulrich Saur, Dieter |
author_sort | Schneider, Günter |
collection | PubMed |
description | The incidence and lethality of pancreatic ductal adenocarcinoma (PDAC) will continue to increase in the next decade. For most patients, chemotherapeutic combination therapies remain the standard of care. The development and successful implementation of precision oncology in other gastrointestinal tumor entities point to opportunities also for PDAC. Therefore, markers linked to specific therapeutic responses and important subgroups of the disease are needed. The MYC oncogene is a relevant driver in PDAC and is linked to drug resistance and sensitivity. Here, we update recent insights into MYC biology in PDAC, summarize the connections between MYC and drug responses, and point to an opportunity to image MYC non-invasively. In sum, we propose MYC-associated biology as a basis for the development of concepts for precision oncology in PDAC. |
format | Online Article Text |
id | pubmed-8511206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-85112062021-10-27 Rationale for MYC imaging and targeting in pancreatic cancer Schneider, Günter Wirth, Matthias Keller, Ulrich Saur, Dieter EJNMMI Res Review The incidence and lethality of pancreatic ductal adenocarcinoma (PDAC) will continue to increase in the next decade. For most patients, chemotherapeutic combination therapies remain the standard of care. The development and successful implementation of precision oncology in other gastrointestinal tumor entities point to opportunities also for PDAC. Therefore, markers linked to specific therapeutic responses and important subgroups of the disease are needed. The MYC oncogene is a relevant driver in PDAC and is linked to drug resistance and sensitivity. Here, we update recent insights into MYC biology in PDAC, summarize the connections between MYC and drug responses, and point to an opportunity to image MYC non-invasively. In sum, we propose MYC-associated biology as a basis for the development of concepts for precision oncology in PDAC. Springer Berlin Heidelberg 2021-10-12 /pmc/articles/PMC8511206/ /pubmed/34637026 http://dx.doi.org/10.1186/s13550-021-00843-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Schneider, Günter Wirth, Matthias Keller, Ulrich Saur, Dieter Rationale for MYC imaging and targeting in pancreatic cancer |
title | Rationale for MYC imaging and targeting in pancreatic cancer |
title_full | Rationale for MYC imaging and targeting in pancreatic cancer |
title_fullStr | Rationale for MYC imaging and targeting in pancreatic cancer |
title_full_unstemmed | Rationale for MYC imaging and targeting in pancreatic cancer |
title_short | Rationale for MYC imaging and targeting in pancreatic cancer |
title_sort | rationale for myc imaging and targeting in pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511206/ https://www.ncbi.nlm.nih.gov/pubmed/34637026 http://dx.doi.org/10.1186/s13550-021-00843-1 |
work_keys_str_mv | AT schneidergunter rationaleformycimagingandtargetinginpancreaticcancer AT wirthmatthias rationaleformycimagingandtargetinginpancreaticcancer AT kellerulrich rationaleformycimagingandtargetinginpancreaticcancer AT saurdieter rationaleformycimagingandtargetinginpancreaticcancer |